Welcome to our dedicated page for Acrivon Therapeutics news (Ticker: ACRV), a resource for investors and traders seeking the latest updates and insights on Acrivon Therapeutics stock.
Acrivon Therapeutics, Inc. develops precision oncology medicines using its proprietary Generative Phosphoproteomics AP3 platform for drug design and predictive clinical development. The company’s recurring news centers on ACR-368, also known as prexasertib, a CHK1/2 inhibitor being developed with the ACR-368 OncoSignature assay for endometrial cancer, as well as ACR-2316, a WEE1/PKMYT1 inhibitor, and ACR-6840, a CDK11 development candidate.
Company updates commonly cover clinical and preclinical oncology data, scientific meeting presentations, FDA Fast Track and Breakthrough Device designations tied to ACR-368 and its assay, financial results, equity award disclosures, and the company’s internal CLIA-certified laboratory for patient testing and companion diagnostic development.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.